V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10406306 | 10071223 | 1.66 | 94.5 | 03 | 2019-09-28 | 2019-12-05 | BUSULFAN | 02 | N | DABRAFENIB | 101444411 |
| 10408909 | 10071224 | 1.91 | 57.8 | Palliative (P) | 2000-01-01 | 2018-10-11 | Acalabrutinib | 02 | N | CISPLATIN | 101262958 |
| 10409363 | 10071225 | 1.82 | 78.4 | null | 2019-08-25 | 2019-09-02 | Bortezomib (weekly) | 02 | null | BORTEZOMIB | 101422272 |
| 10409542 | 10071226 | 1.63 | 57 | Curative (C) | 2021-01-18 | 2021-01-18 | DABRAFENIB + TRAMETINIB | null | N | DABRAFENIB + TRAMETINIB | 100586671 |
| 10410827 | 10071227 | null | 87 | null | 2020-07-28 | 2020-09-08 | CISPLATIN + VINORELBINE + RT | 02 | null | VINORELBINE | 101432799 |
| 10411344 | 10071228 | 1.85 | 67.3 | Palliative (P) | 2020-11-19 | 2020-12-18 | Capecitabine (21 day) + Irinotecan | 2 | N | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 101332368 |
| 10412394 | 10071230 | 1.66 | 61.3 | Palliative (P) | 2018-01-18 | 2018-01-31 | Bortezomib (weekly) | 02 | N | BORTEZOMIB | 100190269 |
| 10412690 | 10071231 | 1.67 | 58.9 | null | 2022-01-29 | 2022-02-26 | Trifluridine + Tipiracil | 02 | null | TIPIRACIL + TRIFLURIDINE | 100651306 |
| 10413115 | 10071232 | 1.85 | 72 | Palliative (P) | 2019-09-01 | 2019-09-02 | Cabazitaxel | 02 | N | CABAZITAXEL | 100287870 |
| 10413781 | 10071234 | 1.65 | 0 | Palliative (P) | 2020-01-19 | 2020-01-19 | Oxaliplatin + Modified de Gramont | 02 | N | VISMODEGIB | 100236851 |
| 10414088 | 10071235 | 0 | 78 | null | 2019-09-27 | 2019-09-27 | Sunitinib | 02 | null | CARFILZOMIB | 101747330 |
| 10414738 | 10071236 | null | null | null | 2017-10-09 | 2019-11-15 | ETOPOSIDE | null | null | CYTARABINE + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 100011192 |
| 10415757 | 10071238 | 1.6 | 69.1 | Palliative (P) | 2017-03-04 | 2017-03-11 | RIALTO TRIAL | 02 | N | CARBOPLATIN + LIPOSOMAL DOX | 100657848 |
| 10415900 | 10071239 | null | null | null | null | 2020-04-25 | LORLATINIB | 02 | null | DURVALUMAB | 101412971 |
| 10416647 | 10071240 | 1.55 | 51.7 | Palliative (P) | 2018-01-11 | 2018-03-14 | CHOP R - 21 days | N | N | SUNITINIB | 100367459 |
| 10417251 | 10071241 | 1.69 | null | 03 | 2019-02-24 | 2019-03-30 | CYTARABINE | 02 | N | TRANSPLANT CYCLOPHOSPHAMIDE + FLUDARABINE + TREOSULFAN | 101112452 |
| 10417622 | 10071242 | 1.64 | 55.7 | Palliative (P) | null | 2020-10-20 | ICE-R | 02 | N | THALIDOMIDE | 101605680 |
| 10418509 | 10071244 | 1.75 | 82.8 | null | 2018-09-13 | 2018-09-13 | LIPOSOMAL DAUNORUBICIN + CYTARABINE (Vyxeos) | 02 | null | TOPOTECAN | 101204312 |
| 10418578 | 10071245 | 1.83 | 94.9 | null | null | 2020-01-30 | AZACITIDINE + VENETOCLAX | null | null | LEAM | 100713107 |
| 10419090 | 10071246 | 1.5 | 57.75 | Palliative (P) | 2020-02-22 | 2020-03-01 | null | 02 | N | LIPOSOMAL DOXORUBICIN | 100035807 |
| 10419189 | 10071247 | 1.63 | 0 | null | 2021-10-14 | 2021-10-14 | FLUOROURACIL + MITOMYCIN | 02 | null | PARTNER TRIAL | 101301716 |
| 10420727 | 10071248 | 1.66 | 67 | null | 2019-09-26 | 2019-10-06 | Lomustine | 02 | null | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100157235 |
| 10420990 | 10071249 | 0 | 84 | null | 2018-09-20 | 2018-10-22 | Erlotinib | 02 | null | FLAIR TRIAL | 100339899 |
| 10421926 | 10071251 | 1.55 | 77.8 | Palliative (P) | 2020-03-25 | 2020-05-27 | Panitumumab | 02 | N | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE | 101205507 |
| 10422194 | 10071252 | null | null | null | 2015-05-24 | 2017-05-20 | LENALIDOMIDE + RITUXIMAB | null | null | PANITUMUMAB | 100340854 |
| 10422545 | 10071253 | 1.81 | 87 | null | 2018-01-04 | 2018-02-07 | ISATUXIMAB + POMALIDOMIDE | 02 | null | NILOTINIB | 101696199 |
| 10423209 | 10071255 | 1.68 | 107.4 | null | 2021-12-07 | 2022-01-02 | Bexarotene | 02 | null | BCG | 100991386 |
| 10425272 | 10071261 | null | null | Neo-adjuvant (N) | null | 2019-08-04 | Doxorubicin + Olaratumab | 02 | null | GEFITINIB | 100998880 |
| 10426029 | 10071264 | 1.68 | 61.3 | Palliative (P) | 2018-06-24 | 2019-01-26 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | BENDAMUSTINE + OBINUTUZUMAB | 101147227 |
| 10427838 | 10071269 | 1.93 | 61.4 | Disease modification (D) | 2018-09-05 | 2018-09-13 | Fulvestrant + Palbociclib | 02 | N | FCR | 100875392 |
| 10430215 | 10071272 | 1.77 | 106.5 | Curative (C) | 2021-03-19 | 2021-03-30 | CARBO + FLUOROURACIL | 02 | N | CAPECITABINE + CISPLATIN | 100568798 |
| 10431192 | 10071274 | 1.8 | 93.4 | Curative (C) | null | 2022-03-14 | CHOP - 21 days | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101121873 |
| 10431408 | 10071275 | 0 | 84.5 | null | 2022-02-25 | 2022-04-02 | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 02 | null | FLUOROURACIL + MITOMYCIN | 100352002 |
| 10431550 | 10071276 | 1.63 | 106.5 | Palliative (P) | 2019-09-14 | 2019-09-16 | null | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 101823083 |
| 10434009 | 10071278 | 1.7 | 64.8 | Disease modification (D) | 2020-01-04 | 2020-01-04 | ATEZOLIZUMAB + BEVACIZUMAB | 02 | N | THALIDOMIDE | 101751455 |
| 10436800 | 10071282 | 1.58 | 102 | Disease modification (D) | 2018-04-14 | 2018-04-26 | AXITINIB | 02 | N | BCG | 101460756 |
| 10437192 | 10071284 | null | null | 03 | 2020-04-26 | 2020-05-05 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | AXITINIB | 100214368 |
| 10437947 | 10071285 | 1.58 | 95 | null | 2022-01-28 | 2022-01-31 | CVP R | 02 | null | OBINUTUZUMAB | 100152227 |
| 10438324 | 10071286 | 1.68 | 93.3 | null | 2020-11-07 | 2020-11-15 | CHOP R - 21 days | N | null | OSIMERTINIB | 101721919 |
| 10439306 | 10071288 | 1.59 | 52.1 | null | 2018-10-27 | 2018-10-27 | FLUOROURACIL + OXALIPLATIN | 02 | null | RUCAPARIB | 101529428 |
| 10439777 | 10071289 | 1.55 | 89.7 | null | 2021-09-27 | 2021-10-10 | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 02 | null | BORTEZOMIB + MELPHALAN | 101179068 |
| 10440602 | 10071291 | 1.61 | 75 | null | 2022-02-24 | 2022-02-24 | PACLITAXEL + TRASTUZUMAB | N | null | PENTOSTATIN + RITUXIMAB | 101184031 |
| 10441740 | 10071294 | 1.58 | 71.5 | 03 | 2022-02-28 | 2022-02-28 | STAR TRIAL | N | N | CYCLOPHOSPHAMIDE + CYTARABINE + ETOPOSIDE + LOMUSTINE | 100490571 |
| 10443050 | 10071296 | 1.63 | 53.4 | Adjuvant (A) | 2018-07-25 | 2019-01-28 | Oxaliplatin + Raltitrexed | 02 | N | RIBOCICLIB | 100517493 |
| 10443134 | 10071298 | 1.83 | 88.3 | null | 2017-02-18 | 2017-02-19 | Cisplatin +Fluorouracil (3 wk) | 02 | null | BENDAMUSTINE + CYTARABINE + RITUXIMAB | 101088808 |
| 10443345 | 10071299 | 0 | 50.2 | null | 2021-03-21 | 2021-11-15 | ECX | 02 | null | BLEOMYCIN + CHLORAMBUCIL + LOMUSTINE + METHOTREXATE + VINBLASTINE | 101810969 |
| 10443658 | 10071300 | 1.69 | 67.6 | null | 2019-06-09 | 2019-06-30 | Capecitabine (14 days)+Carboplatin | 02 | null | MERCAPTOPURINE | 100368663 |
| 10443699 | 10071301 | 1.6 | 79.6 | null | 2019-06-20 | 2019-06-20 | CYTARABINE | 02 | null | ELOQUENT2 TRIAL | 100521879 |
| 10444165 | 10071303 | 1.71 | 61.3 | null | 2019-08-14 | 2019-08-20 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | null | CVD | 100926689 |
| 10445399 | 10071306 | 1.85 | 0 | Adjuvant (A) | 2018-12-30 | 2019-01-30 | FEC 60 or 75 | 02 | N | BEVACIZUMAB | 100709390 |